{"schema_version":"secwatch.filing_event.v1","accession":"0001005286-25-000146","form_type":"8-K","ticker":"LFCR","cik":"0001005286","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.489903+00:00","generated_at":"2026-05-16T23:17:17.058759+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"confidence":"high","headline":"Lifecore Biomedical Q1 revenue up 26% to $31.1M; Adjusted EBITDA turns positive at $3.1M","bullets":["Revenue $31.1M (+26% YoY), driven by HA manufacturing (+$4.8M) and CDMO growth.","Net loss narrowed to $10.0M ($0.29 loss per share) from $16.2M ($0.53) a year ago.","Adjusted EBITDA of $3.1M vs negative $1.8M in prior year; SG&A down $5.9M.","Affirms transition period guidance: revenue $74-76M, Adjusted EBITDA $12-14M.","Signed 4 new programs (2 post-quarter); commercial site transfer with large pharma."],"urls":{"canonical":"https://secwatch.observer/filing/0001005286-25-000146","json":"https://secwatch.observer/filing/0001005286-25-000146.json","markdown":"https://secwatch.observer/filing/0001005286-25-000146.md","text":"https://secwatch.observer/filing/0001005286-25-000146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000146/0001005286-25-000146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1005286/000100528625000146/lndc-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:17:17.058759+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}